Company profile: Reata Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies for cancer, inflammation, neurodegenerative, renal, cardiovascular, and autoimmune diseases, including antioxidant and inflammation-modulating drugs and agents that correct protein misfolding. Offers Skyclarys (omaveloxolone), an FDA-approved treatment for Friedreich's Ataxia in patients 16+.
Products and services
- Skyclarys (omaveloxolone): FDA-approved therapeutic for Friedreich's Ataxia in adults and adolescents aged 16+, addressing a rare, genetic, neurodegenerative disorder
- Multiple Sclerosis (MS) Treatments: Neurodegeneration-focused therapies developed to improve patient outcomes, leveraging research on nerve repair to advance and refine multiple MS treatment products
- Alzheimer’s Disease Research: Early-stage clinical program conducting trials and research to address neurological changes and mild cognitive impairment in Alzheimer’s disease cohorts
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Reata Pharmaceuticals
Paladin Labs
HQ: Canada
Website
- Description: Provider of innovative pharmaceutical products, headquartered in Montreal, Canada, specializing in researching, developing, acquiring, and in-licensing for the Canadian and world markets, supported by a focused national sales team and proven marketing expertise.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paladin Labs company profile →
Prolong Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical products and development technologies, including PP-007 (Sanguinate), a PEGylated carboxyhemoglobin bovine product designed to deliver oxygen and carbon monoxide to hypoxic tissues to restore homeostasis and reduce inflammation, and PEGfinity, a PEGylation-based process that enhances the function and stability of therapeutic proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prolong Pharmaceuticals company profile →
Paion
HQ: Germany
Website
- Description: Provider of biopharmaceutical products; develops and commercializes drug candidates for diseases or interventions with substantial unmet medical need. Lead compound: remimazolam, an intravenous, ultra-short-acting, controllable benzodiazepine. Portfolio: Byfavo (procedural sedation, general anesthesia); Angiotensin II/GIAPREZA (refractory hypotension in septic or distributive shock); Eravacycline/XERAVA (complicated intra-abdominal infections in adults).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paion company profile →
Centessa Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies and platforms, including SerpinPC, a biologic for hemophilia that inhibits activated protein C to reduce bleeding; an Orexin Receptor 2 agonist program for sleep-wake disorders; the LockBody technology platform designed to enhance immuno-oncology by selectively targeting the tumor microenvironment; and LB101, a conditionally tetravalent PD-L1 X CD47 bispecific monoclonal antibody for advanced solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Centessa Pharmaceuticals company profile →
NPS Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapies for rare diseases, dedicated to making a difference in the lives of patients who often have few, if any, treatment options.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NPS Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Reata Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Reata Pharmaceuticals
2.2 - Growth funds investing in similar companies to Reata Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Reata Pharmaceuticals
4.2 - Public trading comparable groups for Reata Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →